<DOC>
	<DOCNO>NCT00317967</DOCNO>
	<brief_summary>The purpose study determine drug call atorvastatin reduce size stiffness muscle leave ventricle heart .</brief_summary>
	<brief_title>Study Determine Atorvastatin Reduces Size Stiffness Muscle Left Ventricle Heart</brief_title>
	<detailed_description>Hypertrophic cardiomyopathy ( HCM ) primary disorder heart characterize thicken , fibrotic myocardium , without dynamic leave ventricular outflow tract gradient . It common heritable cardiovascular disease , population prevalence 0.1 % 0.2 % . Symptoms congestive heart failure extremely common patient HCM . Progression disable debilitate symptom [ New York Heart Association ( NYHA ) class III IV ] relatively common , occur 15 % 20 % unselected population . The rate progression NYHA class III IV death heart failure stroke high , relative risk 2.7 . Management symptom challenge , involve multiple medication , 5 % patient may develop drug refractory heart failure , require invasive intervention . HCM common cause sudden death among young competitive athlete . Ventricular tachyarrhythmias appear primary mechanism ; however , arrhythmia involve include asystole , rapid atrial fibrillation , electrical mechanical dissociation . Patients may develop progressive myocardial wall thinning , reduction systolic performance , increase leave ventricular dimension . Progressive wall thinning may especially common patient initially severe hypertrophy . There cure condition . There evidence animal human study treatment promise reverse hypertrophy - HMG CoA reductase inhibitor . Clearly , study treatment might cause regression hypertrophy timely important .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>18 year HCM absence another cardiac systemic disease capable produce prespecified wall thickening Required use statin therapy intolerance A clinical diagnosis hypertension Indication statin therapy primary secondary prevention coronary artery disease Current anticipate indication â‰¤ 1 year implantable cardioverter defibrillator metallic device prevent cardiac magnetic resonance imaging ( MRI ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Hypertrophic cardiomyopathy</keyword>
	<keyword>Statin therapy</keyword>
	<keyword>Regression</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Arrhythmias</keyword>
	<keyword>Sudden cardiac death</keyword>
</DOC>